| アブストラクト | OBJECTIVES: The present study aimed to estimate the reporting rates (RRs) of acute kidney injury (AKI) and renal failure (RF) after COVID-19 vaccination in the European Economic Area (EEA) and the United States. METHODS: We retrieved and analyzed pharmacovigilance data on suspected AKI and RF cases and fatalities post COVID-19 vaccination with licensed vaccines reported to EudraVigilance and VAERS between week 52/2020 and week 52/2022 or week 1/2023, respectively. Reporting rates with 95% confidence intervals were estimated per million administered vaccine doses. RESULTS: In total, 4,244 AKI and 1,557 RF suspected cases were notified to EudraVigilance (1,692 AKI/971 RF) and VAERS (2,552 AKI/586 RF) during the study period following the administration of >1.6 billion COVID-19 vaccine doses (EEA: 970,934,453/US: 666,511,603). The overall RRs were 3.03 (95 % CI: 2.94-3.12) for AKI and 1.11 (95 % CI: 1.06-1.17) for RF per million administered vaccine doses. Indices for statistically significant increased risks were found in subjects, especially males, >/=65 years compared to 18-64 years old (AKI: OR = 7.23, 95 % CI: 6.63-7.88, p = 0.000, and RF: OR = 4.74, 95 % CI: 3.99-5.63, p < 0.001). AKI reporting rates were higher in the US, while RF reporting rates were higher in Europe. Both potential side effects were elevated following vectored rather than mRNA vaccines, with the highest reporting rates post AD26.COV2.S vaccination in the US (AKI: RR = 12.24, 95 % CI: 10.66-13.81; RF: RR = 3.17, 95 % CI: 2.36-3.97). There were 1,312 deaths possibly associated with AKI (RR = 0.94, 95 % CI: 0.89-0.99) and 460 deaths possibly associated with RF (RR = 0.33, 95 % CI: 0.30-0.36) per million vaccine doses. Fatalities were lower in Europe than in the US (AKI: OR = 0.25, 95 % CI: 0.22-0.28, p < 0.001; RF: OR = 0.82, 95 % CI: 0.69-0.99, p = 0.036). CONCLUSIONS: AKI and RF may be observed rarely following vaccination against COVID-19. Further studies are warranted to confirm these findings and uncover the underlying pathophysiological mechanism. |
|---|
| ジャーナル名 | Vaccine |
|---|
| Pubmed追加日 | 2023/10/28 |
|---|
| 投稿者 | Anastassopoulou, Cleo; Boufidou, Fotini; Hatziantoniou, Sophia; Vasileiou, Konstantinos; Spanakis, Nikolaos; Tsakris, Athanasios |
|---|
| 組織名 | Department of Microbiology, Medical School, National and Kapodistrian University;of Athens, Athens, Greece. Electronic address: cleoa@med.uoa.gr.;Neurochemistry and Biological Markers Unit, 1(st) Department of Neurology,;Medical School, National and Kapodistrian University of Athens, Athens, Greece.;Laboratory of Pharmaceutical Technology, Department of Pharmacy, School of Health;Sciences, University of Patras, Patras, Greece.;Department of Pharmacy, School of Health Sciences, University of Patras, Patras,;Greece.;of Athens, Athens, Greece. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37891048/ |
|---|
